These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9595988)

  • 1. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group.
    Neurology; 1998 May; 50(5):1366-73. PubMed ID: 9595988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.
    Neurology; 1997 Jul; 49(1):142-6. PubMed ID: 9222182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.
    López-Sendón Moreno JL; García Caldentey J; Trigo Cubillo P; Ruiz Romero C; García Ribas G; Alonso Arias MA; García de Yébenes MJ; Tolón RM; Galve-Roperh I; Sagredo O; Valdeolivas S; Resel E; Ortega-Gutierrez S; García-Bermejo ML; Fernández Ruiz J; Guzmán M; García de Yébenes Prous J
    J Neurol; 2016 Jul; 263(7):1390-400. PubMed ID: 27159993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
    Huntington Study Group HART Investigators
    Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.
    Vitale C; Marconi S; Di Maio L; De Michele G; Longo K; Bonavita V; Barone P
    Mov Disord; 2007 Dec; 22(16):2359-64. PubMed ID: 17894335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.
    Huntington Study Group
    Neurology; 2003 Dec; 61(11):1551-6. PubMed ID: 14663041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of remacemide hydrochloride in Huntington's disease.
    Kieburtz K; Feigin A; McDermott M; Como P; Abwender D; Zimmerman C; Hickey C; Orme C; Claude K; Sotack J; Greenamyre JT; Dunn C; Shoulson I
    Mov Disord; 1996 May; 11(3):273-7. PubMed ID: 8723144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled trial of latrepirdine in Huntington disease.
    Kieburtz K; McDermott MP; Voss TS; Corey-Bloom J; Deuel LM; Dorsey ER; Factor S; Geschwind MD; Hodgeman K; Kayson E; Noonberg S; Pourfar M; Rabinowitz K; Ravina B; Sanchez-Ramos J; Seely L; Walker F; Feigin A;
    Arch Neurol; 2010 Feb; 67(2):154-60. PubMed ID: 20142523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.
    van Vugt JP; Siesling S; Vergeer M; van der Velde EA; Roos RA
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):35-9. PubMed ID: 9221965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
    Puri BK; Leavitt BR; Hayden MR; Ross CA; Rosenblatt A; Greenamyre JT; Hersch S; Vaddadi KS; Sword A; Horrobin DF; Manku M; Murck H
    Neurology; 2005 Jul; 65(2):286-92. PubMed ID: 16043801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.
    Huntington Study Group
    Neurology; 2006 Feb; 66(3):366-72. PubMed ID: 16476934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
    Curtis A; Mitchell I; Patel S; Ives N; Rickards H
    Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids.
    Vaddadi KS; Soosai E; Chiu E; Dingjan P
    Neuroreport; 2002 Jan; 13(1):29-33. PubMed ID: 11924889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
    McGarry A; Kieburtz K; Abler V; Grachev ID; Gandhi S; Auinger P; Papapetropoulos S; Hayden M
    J Huntingtons Dis; 2017; 6(3):189-199. PubMed ID: 28826192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study.
    Kloberg A; Constantinescu R; Nilsson MK; Carlsson ML; Carlsson A; Wahlström J; Haghighi S
    Acta Neuropsychiatr; 2014 Oct; 26(5):298-306. PubMed ID: 25241758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.
    Süssmuth SD; Haider S; Landwehrmeyer GB; Farmer R; Frost C; Tripepi G; Andersen CA; Di Bacco M; Lamanna C; Diodato E; Massai L; Diamanti D; Mori E; Magnoni L; Dreyhaupt J; Schiefele K; Craufurd D; Saft C; Rudzinska M; Ryglewicz D; Orth M; Brzozy S; Baran A; Pollio G; Andre R; Tabrizi SJ; Darpo B; Westerberg G;
    Br J Clin Pharmacol; 2015 Mar; 79(3):465-76. PubMed ID: 25223731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
    Ferreira JJ; Rosser A; Craufurd D; Squitieri F; Mallard N; Landwehrmeyer B
    Mov Disord; 2015 Sep; 30(10):1426-9. PubMed ID: 26175332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
    Brownstein MJ; Simon NG; Long JD; Yankey J; Maibach HT; Cudkowicz M; Coffey C; Conwit RA; Lungu C; Anderson KE; Hersch SM; Ecklund DJ; Damiano EM; Itzkowitz DE; Lu S; Chase MK; Shefner JM; McGarry A; Thornell B; Gladden C; Costigan M; O'Suilleabhain P; Marshall FJ; Chesire AM; Deritis P; Adams JL; Hedera P; Lowen K; Rosas HD; Hiller AL; Quinn J; Keith K; Duker AP; Gruenwald C; Molloy A; Jacob C; Factor S; Sperin E; Bega D; Brown ZR; Seeberger LC; Sung VW; Benge M; Kostyk SK; Daley AM; Perlman S; Suski V; Conlon P; Barrett MJ; Lowenhaupt S; Quigg M; Perlmutter JS; Wright BA; Most E; Schwartz GJ; Lamb J; Chuang RS; Singer C; Marder K; Moran JA; Singleton JR; Zorn M; Wall PV; Dubinsky RM; Gray C; Drazinic C
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33207828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.